$2.52 Billion is the total value of NEA Management Company, LLC's 31 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | EPIZYME INC | $241,584,000 | +42.2% | 6,039,589 | 0.0% | 9.57% | +26.1% | |
| XOOM | XOOM CORP | $160,481,000 | +38.6% | 5,052,935 | 0.0% | 6.36% | +22.9% | |
| CLVS | CLOVIS ONCOLOGY INC | $138,611,000 | -9.2% | 2,279,781 | 0.0% | 5.49% | -19.5% | |
| ECOM | CHANNELADVISOR CORP | $101,381,000 | +132.9% | 2,767,697 | 0.0% | 4.02% | +106.5% | |
| FIO | FUSION-IO INC | $94,244,000 | -6.0% | 7,038,379 | 0.0% | 3.73% | -16.6% | |
| SUPN | SUPERNUS PHARMACEUTICALS INC | $78,065,000 | +14.0% | 10,650,000 | 0.0% | 3.09% | +1.1% | |
| HPTX | HYPERION THERAPEUTICS INC | $75,365,000 | +18.8% | 2,884,221 | 0.0% | 2.99% | +5.4% | |
| MM | MILLENNIAL MEDIA INC | $58,149,000 | -18.8% | 8,224,752 | 0.0% | 2.30% | -28.0% | |
| ADNC | AUDIENCE INC | $32,349,000 | -14.9% | 2,878,005 | 0.0% | 1.28% | -24.5% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $27,957,000 | -4.4% | 5,636,573 | 0.0% | 1.11% | -15.2% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $27,789,000 | +9.7% | 11,676,000 | 0.0% | 1.10% | -2.7% | |
| TRGT | TARGACEPT INC | $24,283,000 | +24.4% | 4,572,999 | 0.0% | 0.96% | +10.3% | |
| ITMN | INTERMUNE INC | $20,625,000 | +59.9% | 1,341,000 | 0.0% | 0.82% | +41.8% | |
| NKTR | NEKTAR THERAPEUTICS | $19,078,000 | -9.5% | 1,825,600 | 0.0% | 0.76% | -19.7% | |
| LNKD | LINKEDIN CORP | $18,815,000 | +38.0% | 76,467 | 0.0% | 0.75% | +22.5% | |
| GLUU | GLU MOBILE INC | $16,524,000 | +25.8% | 5,943,793 | 0.0% | 0.66% | +11.6% | |
| ZHNE | ZHONE TECHNOLOGIES INC | $15,061,000 | +293.8% | 4,781,290 | 0.0% | 0.60% | +249.1% | |
| FOLD | AMICUS THERAPEUTICS INC | $13,115,000 | -0.4% | 5,653,029 | 0.0% | 0.52% | -11.6% | |
| CADX | CADENCE PHARMACEUTICALS INC | $13,043,000 | -7.6% | 2,070,286 | 0.0% | 0.52% | -18.1% | |
| EXEL | EXELIXIS INC | $12,845,000 | +28.2% | 2,207,000 | 0.0% | 0.51% | +13.6% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $11,610,000 | +7.2% | 3,243,150 | 0.0% | 0.46% | -5.0% | |
| ALIM | ALIMERA SCIENCES INC | $10,082,000 | -22.9% | 2,681,250 | 0.0% | 0.40% | -31.5% | |
| TSPT | TRANSCEPT PHARMACEUTICALS INC | $6,636,000 | +5.3% | 2,086,755 | 0.0% | 0.26% | -6.4% | |
| SLTM | SOLTA MED INC | $5,919,000 | -9.2% | 2,859,577 | 0.0% | 0.24% | -19.2% | |
| ARQL | ARQULE INC | $5,872,000 | +0.4% | 2,520,316 | 0.0% | 0.23% | -10.7% | |
| NURO | NEUROMETRIX INC | $95,000 | -17.4% | 57,273 | 0.0% | 0.00% | -20.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-10-30
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.